Association of human myxovirus resistance protein A with severity of COVID-19
Abstract Background In this retrospective cohort study, we explored the correlation of blood human myxovirus resistance protein A (MxA) level with severity of disease in hospitalized COVID-19 patients. Methods All 304 patients admitted for COVID-19 in our hospital until 30th of April 2021 were inclu...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-022-07753-0 |
| _version_ | 1828108313455230976 |
|---|---|
| author | Otto Lehtinen Niklas Broman Matti Waris Tytti Vuorinen Ville Peltola Eliisa Löyttyniemi Jarmo Oksi Thijs Feuth |
| author_facet | Otto Lehtinen Niklas Broman Matti Waris Tytti Vuorinen Ville Peltola Eliisa Löyttyniemi Jarmo Oksi Thijs Feuth |
| author_sort | Otto Lehtinen |
| collection | DOAJ |
| description | Abstract Background In this retrospective cohort study, we explored the correlation of blood human myxovirus resistance protein A (MxA) level with severity of disease in hospitalized COVID-19 patients. Methods All 304 patients admitted for COVID-19 in our hospital until 30th of April 2021 were included in this study. MxA was measured from peripheral blood samples in 268 cases. Patients were divided into groups based on their level of MxA on admission. We studied baseline characteristics and severity of disease on admission based on clinical parameters and inflammatory biomarker levels in each group. Severity of disease during hospitalization was determined by the applied level of respiratory support, by the usage of corticosteroids and by the duration of hospitalization. Results Higher MxA levels on admission were associated with a shorter duration of symptoms before admission, and with more severe disease. Adjusted Odds Ratios for any respiratory support were 9.92 (95%CI 2.11–46.58; p = 0.004) in patients with MxA between 400 μg/L and 799 μg/L (p = 0.004) and 20.08 (95%CI 4.51–89.44; p < 0.001) in patients with MxA ≥ 800 μg/L in comparison with patients with initial MxA < 400 μg/L. The usage of corticosteroids was significantly higher in the high-MxA group (77%) in comparison with the intermediate-MxA group (62%, p = 0.013) and low-MxA group (47%, p < 0.001). Conclusions Higher initial levels of MxA were associated with more severe COVID-19. MxA may be a helpful additional biomarker to predict the severity of the disease. |
| first_indexed | 2024-04-11T10:43:55Z |
| format | Article |
| id | doaj.art-e9544bcf51c244de9ee490877b53b9a1 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-04-11T10:43:55Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-e9544bcf51c244de9ee490877b53b9a12022-12-22T04:29:06ZengBMCBMC Infectious Diseases1471-23342022-09-012211710.1186/s12879-022-07753-0Association of human myxovirus resistance protein A with severity of COVID-19Otto Lehtinen0Niklas Broman1Matti Waris2Tytti Vuorinen3Ville Peltola4Eliisa Löyttyniemi5Jarmo Oksi6Thijs Feuth7Department of Pulmonary Diseases and Clinical Allergology, Turku University Hospital and University of TurkuDepartment of Infectious Diseases, Turku University Hospital and University of TurkuDepartment of Clinical Microbiology, Turku University Hospital and University of TurkuDepartment of Clinical Microbiology, Turku University Hospital and University of TurkuDepartment of Paediatrics and Adolescent Medicine, Turku University Hospital and University of TurkuDepartment of Biostatistics, University of TurkuDepartment of Infectious Diseases, Turku University Hospital and University of TurkuDepartment of Pulmonary Diseases and Clinical Allergology, Turku University Hospital and University of TurkuAbstract Background In this retrospective cohort study, we explored the correlation of blood human myxovirus resistance protein A (MxA) level with severity of disease in hospitalized COVID-19 patients. Methods All 304 patients admitted for COVID-19 in our hospital until 30th of April 2021 were included in this study. MxA was measured from peripheral blood samples in 268 cases. Patients were divided into groups based on their level of MxA on admission. We studied baseline characteristics and severity of disease on admission based on clinical parameters and inflammatory biomarker levels in each group. Severity of disease during hospitalization was determined by the applied level of respiratory support, by the usage of corticosteroids and by the duration of hospitalization. Results Higher MxA levels on admission were associated with a shorter duration of symptoms before admission, and with more severe disease. Adjusted Odds Ratios for any respiratory support were 9.92 (95%CI 2.11–46.58; p = 0.004) in patients with MxA between 400 μg/L and 799 μg/L (p = 0.004) and 20.08 (95%CI 4.51–89.44; p < 0.001) in patients with MxA ≥ 800 μg/L in comparison with patients with initial MxA < 400 μg/L. The usage of corticosteroids was significantly higher in the high-MxA group (77%) in comparison with the intermediate-MxA group (62%, p = 0.013) and low-MxA group (47%, p < 0.001). Conclusions Higher initial levels of MxA were associated with more severe COVID-19. MxA may be a helpful additional biomarker to predict the severity of the disease.https://doi.org/10.1186/s12879-022-07753-0COVID-19SARS-CoV-2Human myxovirus resistance protein AMxA |
| spellingShingle | Otto Lehtinen Niklas Broman Matti Waris Tytti Vuorinen Ville Peltola Eliisa Löyttyniemi Jarmo Oksi Thijs Feuth Association of human myxovirus resistance protein A with severity of COVID-19 BMC Infectious Diseases COVID-19 SARS-CoV-2 Human myxovirus resistance protein A MxA |
| title | Association of human myxovirus resistance protein A with severity of COVID-19 |
| title_full | Association of human myxovirus resistance protein A with severity of COVID-19 |
| title_fullStr | Association of human myxovirus resistance protein A with severity of COVID-19 |
| title_full_unstemmed | Association of human myxovirus resistance protein A with severity of COVID-19 |
| title_short | Association of human myxovirus resistance protein A with severity of COVID-19 |
| title_sort | association of human myxovirus resistance protein a with severity of covid 19 |
| topic | COVID-19 SARS-CoV-2 Human myxovirus resistance protein A MxA |
| url | https://doi.org/10.1186/s12879-022-07753-0 |
| work_keys_str_mv | AT ottolehtinen associationofhumanmyxovirusresistanceproteinawithseverityofcovid19 AT niklasbroman associationofhumanmyxovirusresistanceproteinawithseverityofcovid19 AT mattiwaris associationofhumanmyxovirusresistanceproteinawithseverityofcovid19 AT tyttivuorinen associationofhumanmyxovirusresistanceproteinawithseverityofcovid19 AT villepeltola associationofhumanmyxovirusresistanceproteinawithseverityofcovid19 AT eliisaloyttyniemi associationofhumanmyxovirusresistanceproteinawithseverityofcovid19 AT jarmooksi associationofhumanmyxovirusresistanceproteinawithseverityofcovid19 AT thijsfeuth associationofhumanmyxovirusresistanceproteinawithseverityofcovid19 |